Mesna Injection 200mg (Mesna Ampoules) 200mg/2ml

Mesna Injection 200mg is a sterile solution used to reduce the risk of hemorrhagic cystitis in patients receiving ifosfamide chemotherapy. Each 2ml ampoule contains 200mg of mesna, designed for intravenous administration. Store below 25°C and protect from light. Ideal for oncology support during treatment.

Strength

200mg/2ml

Pack Size

Storage

Below 25°C

Manufacturer / TM Owner

Zydus Life Sciences Ltd

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Mesna injection 200mg is primarily used to prevent hemorrhagic cystitis, a bladder condition caused by certain chemotherapy drugs like ifosfamide. It works by binding to toxic metabolites in the urine, reducing bladder irritation. This medication is commonly prescribed alongside chemotherapy regimens to support patient safety and comfort during treatment.

Side Effects

Mesna injection 200mg helps protect the bladder from irritation caused by chemotherapy by neutralizing harmful metabolites in the urine. Patients may notice reduced bladder discomfort and fewer urinary symptoms during treatment. The solution is clear and designed for direct intravenous use without dilution in most cases.

Precautions & Warnings

Store mesna injection 200mg below 25°C and protect it from light to maintain potency. Keep ampoules in their original packaging until use. Discard any unused portion after opening to prevent contamination. Always check the solution for particles or discoloration before administration.

Avoid Interactions

Mesna is generally well-tolerated and does not typically interact with other medications. However, avoid mixing it with other drugs in the same intravenous line unless compatibility is confirmed. No significant interactions with alcohol or common dietary substances have been reported. Always inform healthcare providers about all medications being taken.

Frequently Asked Questions

It is used to reduce the risk of hemorrhagic cystitis in patients receiving chemotherapy drugs like ifosfamide.

It is given intravenously, typically as directed by a healthcare professional.

Common effects may include headache, nausea, or fatigue, but these vary by patient.

Consult a healthcare provider for personalized advice regarding use during pregnancy.

Store below 25°C and protect from light; discard any unused solution after opening.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.